Loading...
•
Sep 30
Absci Q3 2025 Earnings Report
Absci reported a net loss and a sharp revenue decline in Q3 2025 as it increased R&D investment to support its internal pipeline.
Key Takeaways
Absci posted lower revenue in Q3 2025 while ramping up R&D spending, resulting in a larger net loss. The company reaffirmed its focus on ABS-201 programs and highlighted progress toward clinical trials.
Revenue declined significantly to $378,000 from $1.7 million in Q3 2024
Net loss widened slightly to $28.7 million due to higher R&D spend
Cash and securities rose to $152.5 million, funding operations into H1 2028
ABS-201 program progressing with clinical trial initiation expected in December 2025
Absci
Absci
Forward Guidance
Absci reaffirmed its cash runway into H1 2028 and emphasized accelerated clinical development of ABS-201 for multiple indications.
Positive Outlook
- Phase 1/2a trial for ABS-201 in androgenetic alopecia to begin in December 2025
- ABS-201 expansion into endometriosis with Phase 2 trial expected in Q4 2026
- ABS-101 Phase 1 trial showed extended half-life and favorable safety
- ABS-301 progressing in preclinical validation for squamous cell carcinoma
- Cash position strengthened to $152.5 million
Challenges Ahead
- Significant YoY decline in quarterly revenue
- Increased R&D expenses leading to higher net loss
- No new revenue partnerships closed during the quarter
- No internal plans to advance ABS-101 beyond Phase 1 at this time
- Continued reliance on external funding and partnerships